Guardant Health pulled in three regulatory or partnership wins across three weeks in April and May 2026, capped by the May 20 FDA approval of the new Guardant360 Liquid CDx with seven inherited companion-diagnostic indications carrying forward from the prior generation. The headline read in trade press was the 100x panel expansion. The structural read inside the company was that every architectural decision behind those three weeks was made years earlier. Understanding the market is only part of the job. Making money, building systems, and getting to where you want to go — those are the problems The Build exists to help you think through, and the most useful structural question that runs through all of them is the one Guardant answered when it set up its first CDx clearance, its first pharma partnership, and its segment-depth strategy. Are you building assets that compound across the next ten launches, or launches that don’t carry anything forward to the next one?
Most Businesses Are Built As Launches, Not Assets
The default first-time founder ships the business as a sequence of launches. The first product is the first launch. The first cleared label is the first regulatory milestone. The first paying customer is the first commercial proof point. The first pharma or distribution partner is the first commercial deal. Each one is treated as a discrete win on the operating plan, and each one is sized against the next-quarter revenue or the next-milestone fundraise. The build-phase logic is that the company executes one launch at a time, banks the wins, and then sequences the next launch behind it. The cost of the launch-by-launch logic shows up at the second and third launches, because the regulatory work the team did on the first launch does not carry forward, the partnership the team negotiated on the first launch does not deepen, and the customer base the team assembled on the first launch does not compound into the next one.
The version of the business that produces durable enterprise value is the one designed as a compounding asset from the start. Each launch is sized against what it sets up for the next two launches rather than against what it returns in the next quarter alone. The regulatory submission, the partnership structure, the customer agreement, and the engineering platform are all designed so the second launch starts with the inherited value of the first one already in place. The cost of that design discipline is real and visible at the build-phase stage. The engineering investment is higher, the partnership negotiations are longer, the regulatory submissions are more complex. The return on that cost is the structural defensibility the buy-side prices at the deal stage, the multi-launch reference base the customer side reads at the pursuit stage, and the operating leverage the team experiences across the second, third, and fourth product launches.
The Guardant sequence across April and May 2026 is the cleanest current public example of what the compounding architecture buys. Seven inherited CDx indications on the day of the new Liquid CDx approval. A third ESR1 CDx clearance that builds on the prior two. A multi-year pipeline-level pharma partnership that turns one relationship into multiple labels. The compounding wasn’t produced by anything that happened in May 2026. The May 2026 results are what the prior architectural decisions produced.
Architectural Decisions That Make a Business Compound
Three architectural categories make the difference between a launch-by-launch business and a compounding asset. The first is the inheritance architecture in the regulatory, IP, and quality-system work. Each submission, patent application, and quality record is designed so that the next product can pick up the prior work rather than re-derive it. The submission template, the supporting evidence, the labeling structure, and the quality records are all sized for the multi-launch case, even when the current launch only requires the single-product version. The cost is higher at the first launch and lower at every launch after it.
The second is the segment-depth strategy in the commercial work. Rather than spreading launches across unrelated segments to chase opportunistic revenue, the business accumulates multiple wins inside one segment before stepping into the next one. The first cleared label, the first reference customer, the first published clinical or technical result, and the first commercial partnership all stack inside the same segment, and each accumulating win makes the next one easier to land. The competing point-product entrant has to displace not one but three or four accumulated wins in the same segment, and the buyer side reads the segment depth as a structurally different category of supplier.
The third is the partnership structure in the business-development work. Each commercial, distribution, or pharma agreement is sized at the pipeline or portfolio level rather than the program level from the first deal forward. The cost of negotiating a pipeline-level relationship is roughly the same as a program-level relationship, and the difference shows up as multiple commercial outcomes per partnership across the build phase. The first partnership the company writes is the model the entire partnership portfolio is built against, and the contract template, the governance structure, and the commercial rhythm are all designed so that the next partnership signs against the same architecture.
What the Guardant Sequence Shows About the Compounding Calendar
The compounding architecture pays back on a calendar the operating plan has to be sized against from the start. The first 12 to 18 months of a compounding business look slower than the launch-by-launch alternative because the regulatory, partnership, and engineering work is sized for the multi-launch case rather than the single-launch case. The next 12 to 18 months look comparable on revenue but structurally different on the underlying asset base, because the second launch begins to inherit from the first. The 36-to-60-month window is where the compounding architecture diverges from the launch-by-launch alternative on every operating metric the buy-side prices. The accumulated regulatory labels, the accumulated commercial relationships, the accumulated segment depth, and the accumulated reference base all sit on top of each new launch, and the operating leverage shows up as faster time-to-revenue per launch, lower customer-acquisition cost per launch, and higher multiple at the financing or exit moment. The Guardant sequence is the visible compounding moment for a business architected on the multi-year horizon a decade ago. The decisions that produced the moment were made structurally early in the company’s build.
From a recent issue
Designing the First Clearance So the Next Three Inherit From It
The default first-time founder ships the first regulatory clearance against the narrowest acceptable label so the submission clears quickly. The issue covers how to size the submission, the supporting evidence, and the labeling architecture so the next two or three products can transfer labels forward rather than re-derive them, and how to write the operating plan against the multi-launch inheritance calendar instead of the single-launch milestone calendar.
From a recent issue
Picking the Segment You Are Going to Compound Inside
The default first-time founder takes the first opportunistic deal in front of them and ships into whichever segment the deal opens. The issue covers how to pick the segment the business intends to accumulate three or four wins inside across the next 36 months, how to design the first deal against the segment-depth strategy rather than the opportunistic-revenue strategy, and how to walk away from the deal that pulls the business out of the compounding lane.
From a recent issue
Writing the First Partnership at the Pipeline Level
The default first-time founder negotiates the first commercial partnership as a program-specific engagement against the first product the partner is interested in. The issue covers how to structure the first partnership as a pipeline-level commitment that turns one relationship into multiple commercial outcomes, what the contract template, governance structure, and commercial rhythm look like inside a pipeline-level agreement, and how the partnership portfolio compounds when every deal is signed against the same architecture.
Why physical and monthly
The format is part of the point
The Build arrives printed and mailed once a month. Not weekly. Not digital. The architectural decisions that produce a compounding business are durable, and they benefit from a reading environment that sits outside the notification stream and the ambient pressure to respond to everything immediately. Subscribers annotate their issues, keep them on a shelf, and return to them when the architectural decision the company made 18 months ago is the question the board is asking again this quarter. That kind of return-and-reread rarely happens with a digital newsletter that scrolls past on a Tuesday morning.
The Build
The best newsletter for making money, building systems, and getting to where you want to go
Monthly. Physical. Mailed to subscribers. Built for founders who are serious about the architectural questions that determine whether the business compounds across the next ten launches or starts from zero on every one of them.
30-day trial period
$14.95 — then $79/month